Product Description
GT-02287 is being developed by GAIN Therapeutics for the treatment of Parkinson's disease. (Sourced from: https://www.gaintherapeutics.com/investors-media/news-and-events/53-newsroom/press-releases/2020news/386-ainherapeuticsresentsewreclinicalataemonstrati20220919050503.html)
Mechanisms of Action: GCase Enhancer
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: GAIN Therapeutics
Company Location: Eastern America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 4
Recent & Upcoming Milestones
- Clinical Outcomes Expected - GAIN Therapeutics announced they will present P1 Parkinson's Disease results in 4Q26 for GT-02287
- Clinical Outcomes Reported - GAIN Therapeutics presented P1 Parkinson's Disease results on 2026-05-22 for GT-02287
- Clinical Trial Start Expected - GAIN Therapeutics announced they will initiate a P2 Parkinson's Disease trial in 3Q26 for GT-02287
Highest Development Phases
Phase 2: Parkinson's Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07280299 |
GANX-001-V103 | P2 |
Not yet recruiting |
Parkinson's Disease |
2028-06-30 |
12% |
2025-12-13 |
Primary Endpoints|Treatments |
NCT06732180 |
GANX-001-V102 | P1 |
Recruiting |
Parkinson's Disease |
2025-11-30 |
50% |
2025-02-26 |
Primary Endpoints|Start Date|Treatments|Trial Status |
ACTRN12625000473460 |
ACTRN12625000473460 | P1 |
Completed |
Parkinson's Disease |
2025-06-27 |
2026-02-15 |
Treatments |
|
ACTRN12623000860662 |
ACTRN12623000860662 | P1 |
Completed |
Parkinson's Disease |
2024-06-20 |
2026-02-15 |
Patient Enrollment|Primary Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/19/2026 |
News Article |
Gain Therapeutics to Present at the 38th Annual ROTH Conference |
|
03/18/2026 |
News Article |
Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026 |
|
03/12/2026 |
News Article |
Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update |
|
01/07/2026 |
News Article |
Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week |